

GRANTING OF ASX WAIVER – U.S. FINANCIAL REPORTING REQUIREMENTS

27 May 2026 – Melbourne, Australia (26 May 2026 – Minneapolis, United States) – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) advises that its registration statement on Form 10 became effective on 17 May 2026 (U.S. time). As such, Imricor is now a U.S. public reporting company and is subject to the periodic reporting requirements of the U.S. Securities and Exchange Act of 1934, including the requirements to file annual reports on Form 10-K, quarterly reports on Form 10-Q and periodic reports on Form 8-K with the U.S. Securities and Exchange Commission (**SEC**).

Imricor, as an ASX listed entity, is also subject to the periodic reporting requirements set out in Chapter 4 of the ASX Listing Rules.

Imricor has been granted a waiver from ASX Listing Rules 4.2A.3, 4.3A, 4.7B and 4.7C effective from 26 May 2026. The purpose of the waiver is to align Imricor's ASX periodic reporting with the reporting requirements in its home jurisdiction in the U.S. as requiring two sets of periodic reports would impose unnecessary duplication where market disclosure would not be improved. The waiver will cease to apply if Imricor ceases to be subject to an obligation to file Forms 10-K and Forms 10-Q with the SEC under U.S. law.

The table below summarises the effect of the waiver on the timeframes in which Imricor must file financial reports with the SEC compared to the timeframes that, absent the waiver, Imricor would have had to lodge certain financial reports with the ASX. Financial reports filed by Imricor with the SEC will also be released to the ASX.

The table also notes any waiver requirements in addition to timing. For example, ASX requires that any information usually required under the relevant ASX periodic report, and that is not otherwise covered by the corresponding SEC filing, will be included with the filing.

Listing Rule	Standard ASX lodgement timeframe	Waiver	Imricor's lodgement timeframe as result of the waiver
4.2A.3	Imricor must lodge with the ASX an Appendix 4D within two months after the end of its half year	Imricor will not be required to lodge an Appendix 4D, on the condition that the Company gives the ASX: <ul style="list-style-type: none"> (i) a copy of Form 10-Q the Company has filed with the SEC for the first and second quarters of that financial year; and (ii) in the case of the Company's Form 10-Q for the second quarter, a cover sheet for the Form 10-Q headed "Results for announcement to the market" with key information set out in section 2 of Appendix 4D. 	Imricor will lodge its Form 10-Q and the cover sheet for the second quarter with ASX by the earliest of: <ul style="list-style-type: none"> (i) the date it is filed with the SEC; and (ii) the date it is due to be given to the SEC under U.S. law (currently within 45 days after the end of the second quarter).
4.3A	Imricor must lodge with the ASX an Appendix 4E within two months after the	Imricor will not be required to lodge an Appendix 4E, on the condition that the Company gives the ASX:	Imricor will lodge its Form 10-K and the cover sheet with ASX by the earliest of:

Listing Rule	Standard ASX lodgement timeframe	Waiver	Imricor's lodgement timeframe as result of the waiver
	end of its financial year.	(i) a copy of the Form 10-K that it has filed with the SEC for that financial year; and (ii) a cover sheet for the Form 10-K headed "Results for announcement to the market" with the key information set out in section 2 of Appendix 4E.	(i) the date it is filed with the SEC; (ii) the date it is due to be given to the SEC under U.S. law (currently within 90 days following the end of Imricor's financial year); and (iii) the date that its Appendix 4E and accounts are due for lodgement with ASX under Listing Rule 4.3A.
4.7B & 4.7C	Imricor must lodge with the ASX an Appendix 4C within one month after the end of each quarter of its financial year. Imricor must lodge with the ASX a quarterly activity report that accompanies the Appendix 4C filed within one month after the end of each quarter of its financial year.	Imricor will not be required to lodge an Appendix 4C, on the condition that the Company gives the ASX: <ul style="list-style-type: none"> (i) for the first, second and third quarters of its financial year, a copy of Forms 10-Q the Company has filed with the SEC for those quarters; (ii) for the fourth quarter of its financial year, a copy of the Form 10-K the Company has filed with the SEC for that financial year; and (iii) for each quarter, if there is any information that ought to have been disclosed in the Company's quarterly activity report for that quarter under Listing Rule 4.7C that is not included in the Company's Form 10-Q or Form 10-K, a supplement to the Form 10-Q or Form 10-K that discloses the information. 	Imricor will lodge its Form 10-Q within 45 days following the end of the first, second and third quarters of its financial year and, for the fourth quarter of its financial year, a copy of the Form 10-K filed by the earliest of: <ul style="list-style-type: none"> (i) date the 10-K was filed with the SEC; (ii) the date it is due to be given to the SEC under U.S. law (currently within 90 days following the end of Imricor's financial year); and (iii) the date that its Appendix 4E and accounts are due for lodgement with ASX under Listing Rule 4.3A.

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

ENDS

For personal use only



Media and Investor Relations Contacts

Simon Hinsley
Executive Director, NWR
Email: simon@nwrcommunications.com.au
Mobile: +61 401 909 653

Nick Corkill
VP, Corporate Strategy, Imricor
Email: nick.corkill@imricor.com
Mobile: +61 450 475 633

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance (MR) imaging guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MR's superior imaging capabilities.

Imricor's Products

Imricor is a pioneer and world leader in developing MR-compatible products for cardiac catheter ablation procedures. The Company's products include capital equipment, such as the NorthStar® Mapping System and the Advantage-MR® EP Recorder/Stimulator. Single-use devices include a variety of ablation catheters, diagnostic catheters, steerable sheaths, and other tools used for cardiac ablations.

Imricor's products are approved in the European Union, the Kingdom of Saudi Arabia, and New Zealand. NorthStar is approved in the US.

Foreign Ownership Restrictions

Imricor's CHESS Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons excluding qualified institutional buyers (QIBs, as defined in Rule 144A under the Securities Act). However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.